Apricoxib

Apricoxib structure

Apricoxib: An Experimental COX-2 Inhibitor for Cancer Therapy

Apricoxib represents a novel approach to cancer treatment, specifically targeting the cyclooxygenase-2 (COX-2) enzyme. Currently in Phase II clinical trials, this drug exhibits promise in enhancing therapeutic responses in specific molecular subtypes of pancreatic cancer.

Background

COX-2 Enzyme: The COX-2 enzyme plays a pivotal role in inflammation and is frequently overexpressed in several types of cancers, including pancreatic^[1]. Its role in tumorigenesis and progression has made it an attractive target for anti-cancer strategies.

Mechanism of Action

COX-2 Inhibition: Apricoxib works by selectively inhibiting the COX-2 enzyme, thereby reducing the production of pro-inflammatory and tumorigenic prostaglandins^[2].

Enhanced Therapy Response: By targeting COX-2, apricoxib has the potential to improve the efficacy of standard chemotherapy regimens, particularly in molecularly defined models of pancreatic cancer^[3].

Clinical Development

Apricoxib's journey through clinical evaluation is characterized by:

Phase II Clinical Trials: The drug is currently under Phase II investigation to assess its efficacy, safety profile, and optimal dosing regimen.

Pancreatic Cancer Focus: Special attention is being given to its application in pancreatic cancer, a malignancy with limited treatment options and poor prognosis^[4].

Molecularly Defined Models: Notably, apricoxib's efficacy seems to be pronounced in specific molecular subtypes of pancreatic cancer, suggesting a precision medicine approach to its application.

Future Prospects

While apricoxib is still under evaluation, its mechanism of action and preliminary results suggest a potential breakthrough in the management of pancreatic cancer. If successful, it could pave the way for:

Enhanced combination therapies with existing chemotherapeutic agents.
A potential model for targeting COX-2 overexpression in other cancer types.
Establishing a precedent for molecularly-targeted treatments in pancreatic cancer^[5].

Conclusion

Apricoxib's journey, from molecular targeting to clinical evaluation, exemplifies the modern approach to cancer drug discovery. As research progresses, this compound may offer hope for patients with pancreatic cancer and possibly other malignancies driven by COX-2 overexpression.

References

↑ Yip-Schneider, M. T., et al. (2017). Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 21(2), 139-146.
↑ Williams, C. S., & Mann, M. (2004). Role of cyclooxygenase-2 in tumorigenesis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1704(2), 97-108.
↑ Han, C., et al. (2012). The role of COX-2 in mediating the effect of PTEN loss on PDGFR-driven gliomas. Neoplasia, 14(3), 193-206.
↑ Rahib, L., et al. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research, 74(11), 2913-2921.
↑ Mok, S., et al. (2007). Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Research, 67(2), 583-592.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Transform your life with W8MD's budget GLP-1 injections from $125.

W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:

- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.

NYC weight loss doctor appointments

Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.

Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC

Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

[1] Yip-Schneider, M. T., et al. (2017). Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 21(2), 139-146.

[2] Williams, C. S., & Mann, M. (2004). Role of cyclooxygenase-2 in tumorigenesis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1704(2), 97-108.

[3] Han, C., et al. (2012). The role of COX-2 in mediating the effect of PTEN loss on PDGFR-driven gliomas. Neoplasia, 14(3), 193-206.

[4] Rahib, L., et al. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research, 74(11), 2913-2921.

[5] Mok, S., et al. (2007). Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Research, 67(2), 583-592.

[1]

[2]

[3]

[4]

[5]